SCCM Podcast SCCM Pod-504 CCM: Baricitinib or Tocilizumab for Severe COVID-19
Mar 25, 2024
Podcast discusses the outcomes and adverse effects of Baricitinib versus Tocilizumab for severe COVID-19, comparing mortality rates and drug profiles. They explore the challenges in drug selection, vaccination efficacy, treatment decisions, and research challenges in severe COVID-19 cases. Emphasizes the need for more data and long-term studies on adverse effects.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Comparing Baricitinib and Tocilizumab for Severe COVID-19 Cases
02:29 • 13min
Discussion on Vaccination Efficacy and Drug Dosing Guidelines
15:22 • 2min
Treatment Decision Making and Research Challenges for Severe COVID-19
17:04 • 2min
Exploring Long-Term Data and SCCM Membership
19:03 • 2min